
    
      In this study, eligible subject will be randomized into study arm or control arm to accept
      study treatment. Treatment cycles of chemotherapy will be at most 6 weeks which will be
      decided by investigators. Progression-free survival (PFS) determined by the Independent
      Review Committee (IRC) will be the primary outcome measures.
    
  